Management of persistent fever in the neutropenic patient

American Journal of Medicine

Volumn 108, Issue 4, 2000, Pages 343-345

  Bodey, Gerald P ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; FLUCONAZOLE;

ANTIMICROBIAL THERAPY; ASPERGILLUS; CANDIDA; EDITORIAL; FEBRILE NEUTROPENIA; FEVER; HUMAN; INFECTION; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; FEVER; FLUCONAZOLE; HUMANS; MYCOSES; NEUTROPENIA;

EID: 0033951349     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(99)00453-2     Document Type: Editorial

References (12)

1. Bodey GP, Elting LS, Narro J, et al. An open trial of cefoperazone plus sulbactam for the treatment of fever in cancer patients. J Antimicrob Chemother. 1993;32:141-152.
2. Freifeld AG, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol. 1995;13:165-176.
3. Bodey G, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis. 1992;11:99-109.
4. Bodey GP. Hematogenous and major organ candidiasis. In: Bodey GP, ed. Candidiasis: Pathogenesis, Diagnosis, and Treatment. New York: Raven Press; 1992:279-329.
5. Telenti A, Roberts GD. Fungal blood cultures. Eur J Clin Microbiol Infect Dis. 1989;8:825-831.
6. Walsh TJ, Chanock SJ. Laboratory diagnosis of invasive candidiasis: a rationale for complementary use of culture- and nonculture-based detection systems. Int J Infect Dis. 1997;1:S11-S19.
7. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric therapy and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982;72:101-111.
8. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med. 1989;86:668-672.
9. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with fever. Clin Infect Dis. 1997;25:551-573.
10. Winston DJ, Hathom JW, Schuster MG, et al. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med. 2000;108:282-289.
11. Viscoli C, Castagnola E, Van Lint MT, et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic and randomized clinical trial. Eur J Cancer. 1996;32A:814-820.
12. Büchner T, Silling-Engelhardt G, Fegeler W, Roos N. Early empiric antifungal treatment for febrile neutropenia in patients with hematologic malignancies: fluconazole versus amphotericin B/5-flucytosine. In: Scientific Program and Abstract Book. Second International Symposium on Febrile Neutropenia, Brussels, Belgium; 1995:259.